Table 1 Demographic, clinical and echocardiographic parameters in STEMI patients according to tertiles of DPP4a.

From: Plasma dipeptidyl-peptidase-4 activity is associated with left ventricular systolic function in patients with ST-segment elevation myocardial infarction

U/L

Total

T1

T2

T3

p value

<24.00

24.00–31.50

>31.50

n

584

194

196

194

 

Age (years)

58.00 ± 11.56

59.02 ± 12.07

58.82 ± 11.55

56.15 ± 10.88

0.03

Male, n (%)

491 (84.1)

163 (84.0)

164 (83.7)

164 (84.5)

0.97

BMI

25.80 ± 3.38

25.71 ± 3.31

25.43 ± 3.34

26.27 ± 3.46

0.04

Hypertension, n (%)

323 (55.3)

124 (63.9)

97 (49.5)

102 (52.6)

0.01

Hyperlipidemia, n (%)

62 (10.6)

24 (12.4)

20 (10.2)

18 (9.3)

0.60

Diabetes mellitus, n (%)

118 (20.2)

49 (25.3)

37 (18.9)

32 (16.5)

0.08

Current smoker, n (%)

258 (44.2)

72 (37.1)

90 (45.9)

96 (49.5)

0.04

Ex-smoker, n (%)

80 (13.7)

35 (18.0)

26 (13.3)

19 (9.8)

0.06

Previous MI, n (%)

88 (15.1)

22 (11.3)

29 (14.8)

37 (19.1)

0.10

Previous PCI, n (%)

139 (23.8)

52 (26.8)

44 (22.4)

43 (22.2)

0.49

Previous CABG, n (%)

5 (0.9)

4 (2.1)

0 (0)

1 (0.5)

0.07

Medications, n (%)

Aspirin

581 (99.5)

194 (100)

194 (99.0)

193 (99.5)

0.37

ACEI/ARB

540 (92.5)

181 (93.3)

179 (91.3)

180 (92.8)

0.75

β-blocker

514 (88.0)

176 (90.7)

170 (86.7)

168 (86.6)

0.36

Clopidogrel

571 (97.8)

191 (98.5)

191 (97.4)

189 (97.4)

0.74

Statin

580 (99.3)

193 (99.5)

195 (99.5)

192 (99.0)

0.77

Nitrate

528 (90.4)

181 (93.3)

170 (86.7)

177 (91.2)

0.08

Diuretic

244 (41.8)

85 (43.8)

86 (43.9)

73 (37.6)

0.36

Total cholesterol (mmol/L)

4.09 ± 1.06

3.91 ± 0.98

4.12 ± 1.13

4.24 ± 1.04

0.01

Triglyceride (mmol/L)

1.56 ± 0.83

1.54 ± 0.80

1.47 ± 0.76

1.65 ± 0.91

0.11

LDL cholesterol (mmol/L)

2.52 ± 0.89

2.38 ± 0.81

2.55 ± 0.97

2.62 ± 0.86

0.03

HDL cholesterol (mmol/L)

1.03 ± 0.28

0.99 ± 0.27

1.02 ± 0.27

1.07 ± 0.29

0.02

Plasma glucose (mmol/L)

6.91 ± 2.65

7.11 ± 2.77

6.90 ± 2.87

6.72 ± 2.26

0.34

CK-MB (ng/mL)

2.71 (1.59–18.78)

2.50 (1.51–10.60)

2.64 (1.61–49.06)

3.02 (1.74–30.07)

0.15

cTNT (ng/mL)

0.18 (0.02–1.62)

0.23 (0.02–1.04)

0.17 (0.02–2.06)

0.19 (0.02–1.94)

0.81

peak NT-proBNP (pg/mL)

931 (329–2143)

1136 (302–2629)

1017 (364–2233)

640 (283–1607)

0.04

Creatinine (umol/L)

78.50 (68.73–90.00)

79.30 (65.00–94.73)

79.55 (71.05–91.83)

76.95 (68.90–85.90)

0.11

Echocardiographic parameters

LVEDVi (mL/m2)

57.51 ± 14.82

59.39 ± 17.17

58.10 ± 14.79

55.09 ± 11.80

0.01

LVESVi (mL/m2)

28.18 ± 10.75

30.03 ± 13.04

28.40 ± 10.71

26.12 ± 7.49

<0.01

LVMI (g/m2)

117.84 ± 26.66

121.41 ± 29.95

118.26 ± 25.79

113.90 ± 23.48

0.02

RWT (%)

0.44 ± 0.06

0.44 ± 0.07

0.43 ± 0.06

0.44 ± 0.05

0.25

SV (mL)

53.07 ± 13.52

52.82 ± 14.08

53.44 ± 13.87

52.94 ± 12.64

0.89

E/A ratio

0.81 (0.68–1.14)

0.81 (0.68–1.14)

0.83 (0.68–1.12)

0.79 (0.67–1.16)

0.08

LVEF (%)

51.47 ± 7.91

50.13 ± 9.12

51.44 ± 7.42

52.85 ± 6.82

<0.01

FS (%)

27.96 ± 4.66

27.37 ± 5.18

27.85 ± 4.44

28.68 ± 4.25

0.02

LVSWi (g/cm−2)

0.95 ± 0.22

0.93 ± 0.23

0.95 ± 0.22

0.97 ± 0.20

0.24

LVSD, n (%)

60 (10.3)

32 (16.5)

21 (10.7)

7 (3.6)

<0.01

  1. A, maximum late transmitral velocity in diastole; ACEI, angiotensin-converting enzyme inhibitor; ARB, adrenergic receptor binder; BMI, body mass index; BNP, brain natriuretic peptide; CABG, coronary artery bypass grafting; CK-MB, MB isoenzyme of creatine kinase; cTNT, cardiac troponin T; E, maximum early transmitral velocity in diastole; FS, subendocardial fractional shortening; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LV, left ventricular; LVEDVi, LV end-diastolic volume index; LVEF, LV ejection fraction; LVESVi, LV end-systolic volume index; LVMI, LV mass index; LVSD, LV systolic dysfunction; LVSWi, LV stroke work index; MI, myocardial infarction; PCI, percutaneous coronary intervention; RWT, relative wall thickness; SV, stroke volume. Data are expressed as mean ± SD or median (interquartile range), and categorical variables as numbers and percentages.
Back to article page